SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 201 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,328 | -80.0% | 10,252 | -72.9% | 0.00% | – |
| Q1 2023 | $66,486 | -99.2% | 37,776 | -94.4% | 0.00% | -100.0% |
| Q1 2021 | $8,523,000 | +140.1% | 680,200 | +172.1% | 0.04% | +185.7% |
| Q2 2018 | $3,550,000 | -65.9% | 250,000 | -63.9% | 0.01% | -69.6% |
| Q3 2017 | $10,400,000 | +230.4% | 693,300 | +93.8% | 0.05% | +155.6% |
| Q2 2017 | $3,148,000 | +49.4% | 357,705 | +2.7% | 0.02% | +12.5% |
| Q1 2016 | $2,107,000 | -61.6% | 348,200 | -42.0% | 0.02% | -64.4% |
| Q4 2015 | $5,481,000 | +3325.6% | 600,300 | +2021.2% | 0.04% | +4400.0% |
| Q3 2015 | $160,000 | -95.5% | 28,300 | -91.2% | 0.00% | -96.0% |
| Q2 2015 | $3,552,000 | +15.5% | 320,300 | +63.3% | 0.02% | +19.0% |
| Q1 2015 | $3,075,000 | +28.0% | 196,100 | +24.1% | 0.02% | +23.5% |
| Q4 2014 | $2,403,000 | -80.3% | 158,000 | -86.0% | 0.02% | -81.5% |
| Q3 2014 | $12,186,000 | +1.2% | 1,129,900 | +43.2% | 0.09% | +19.5% |
| Q2 2014 | $12,047,000 | – | 788,900 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lombard Odier Asset Management (Switzerland) SA | 1,539,994 | $11,550,000 | 0.74% |
| Golden State Equity Partners | 143,768 | $1,078,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 765,000 | $5,975,000 | 0.40% |
| WASATCH ADVISORS LP | 10,960,982 | $82,207,000 | 0.34% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $332,000 | 0.32% |
| EMC Capital Management | 61,394 | $460,000 | 0.25% |
| Rokos Capital Management LLP | 539,860 | $4,108,000 | 0.25% |
| Long Focus Capital Management, LLC | 245,000 | $1,838,000 | 0.24% |
| Vanguard Capital Wealth Advisors | 33,380 | $250,000 | 0.18% |
| Fort Sheridan Advisors LLC | 74,898 | $562,000 | 0.16% |